Targeted cryoablation for treating localized prostate cancer

Abstract

Objective To investigate the operative safety and early oncological outcomes of targeted cryoablation for localized prostate cancer. Methods From Jun. 2014 to Dec.2014, the clinical and prognostic data of 12 patients in our center treated with targeted cryoablation for localised prostate cancer were collected and retrospectively analyzed. The age ranged from 75 to 82 years old, mean 78.6 years old. The average preoperative value of PSA was 12.0 ng/ml, ranging 7.3-19.6 ng/ml. Tumors were cT1c in 2 patients, cT2a in 5 patients and cT2b in 5 patients. Nine cases had a biopsy Gleason score of 6 and 3 cases a score of 7. All patients had good continence and bad erectile function before operation. Results The operative duration ranged from 115 to 152 min, mean 126.8 min. The average postoperative hospital stay was 1.9 days, ranging 1 to 3days. All patients had satisfied continence after a 7-day indwelling of catheter. There were Clavien I-II complications in 2 patients after cryoablation. The follow-up ranged from 17.8 to 23.1 months, median 20.0 months. All patients were alive without local progression or metastasis. Four patients developed a biochemical recurrence, and 2 patients received intermittent endocrine therapy, whose PSA values were declining and the last PSA values were 1.1 ng/ml and 2.7 ng/ml, the remaining two patients were normal in the multiparametric MRI and contrast-enhanced ultrasonography, whose PSA values were stable without any therapy and the last PSA values were 7.8 ng/ml and 6.0 ng/ml. Conclusions Targeted cryoablation has advantages of safety, quicker recovery, promising early oncological outcomes and is an appropriate option of single or localized low-risk prostate cancer ineligible for radical surgery. Key words: Prostate cancer; Cryoablation; Targeted